Investment
Features
FeesSafety
Academy
More
Pluang+

Compare James Hardie Industries plc. Ordinary Shares (JHX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

James Hardie Industries plc. Ordinary SharesTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

James Hardie Industries plc. Ordinary Shares vs Regeneron Pharmaceuticals Inc — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $25.18 (market cap $14.29B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.3× James Hardie Industries plc. Ordinary Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while James Hardie Industries plc. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

JHXREGN
Market Cap
$14.29B$76.40B
Volume
10,655,120626,381
Sector
Basic MaterialsHealth
52-Week High
$31.08$852.03
52-Week Low
$16.69$557.73
Typical Hold Time
0 Days107 Days
Enterprise Value
$18.52B$71.12B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

James Hardie Industries plc. Ordinary Shares

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JHX
100% Buy0% Sell
Avg holding period · 0 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

About James Hardie Industries plc. Ordinary Shares

James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.

Read more on JHX →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →